TY - JOUR
T1 - Implementing Pharmacogenomics in Europe
T2 - Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
AU - on behalf of the Ubiquitous Pharmacogenomics Consortium
AU - van der Wouden, C. H.
AU - Cambon-Thomsen, A.
AU - Cecchin, E.
AU - Cheung, K. C.
AU - Dávila-Fajardo, C. L.
AU - Deneer, V. H.
AU - Dolžan, V.
AU - Ingelman-Sundberg, M.
AU - Jönsson, S.
AU - Karlsson, M. O.
AU - Kriek, M.
AU - Mitropoulou, C.
AU - Patrinos, G. P.
AU - Pirmohamed, M.
AU - Samwald, M.
AU - Schaeffeler, E.
AU - Schwab, M.
AU - Steinberger, D.
AU - Stingl, J.
AU - Sunder-Plassmann, G.
AU - Toffoli, G.
AU - Turner, R. M.
AU - van Rhenen, M. H.
AU - Swen, J. J.
AU - Guchelaar, H. J.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.
AB - Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.
UR - http://www.scopus.com/inward/record.url?scp=85012110585&partnerID=8YFLogxK
U2 - 10.1002/cpt.602
DO - 10.1002/cpt.602
M3 - Article
C2 - 28027596
AN - SCOPUS:85012110585
SN - 0009-9236
VL - 101
SP - 341
EP - 358
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 3
ER -